ERBB2 and breast neoplasm: In this manner, PDA NPs loaded with both Tmab and PTX reduced the viability of HER2+ breast tumor cells to a greater or equal extent than the similar reported nanomedicines [16,34], but transporting a smaller amount of PTX and having been administered in a lower concentration to the cells.